For example, detection of emerging EGFR mutations (e.g., deletions in exon 19 and L858R substitutions in exon 21) in patients with non-small cell lung cancer (NSCLC), can guide treatment with EGFR tyrosine kinase inhibitors (TKIs) [13, 14]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.